All In Biotech

Drug Trial Radar · NCT04972656

Treatment With Ambrisentan in Patients With Borderline Pulmonary Arterial Hypertension

Treatment With Ambrisentan in Patients With Borderline Pulmonary Arterial Hypertension: a Multicenter, Randomized, Double-blind, Placebo-controlled Study

Last checked: Nov 20, 2026Latest source record: Sep 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 420 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

420

Planned (sponsor's estimate)

Start

Sep 5, 2022

Primary completion

Dec 30, 2025

Study completion Mar 30, 2026

Sponsor

Lead sponsor
Nanjing First Hospital, Nanjing Medical UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Tianjin Medical University General Hospital
First posted
Jul 22, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An Investigator initiated trial (IIT) using a prospective, randomized, double-blind, parallel group, placebo-controlled, clinical study design.

Conditions

  • Pulmonary Arterial Hypertension

Interventions

  • AmbrisentanDrug

    Titration: Monotherapy using ambrisentan will be initialized at a beginning dose of 5 mg (once daily). Drug intake is scheduled at the morning. After 4 weeks monitoring, the dose of ambrisentan will be uptitrated to 10 mg once daily. Otherwise, if intolerability is indicated, a dose of 5 mg (once daily) will be maintained through the study duration. Maximum dose allowed: not to exceed 10 mg/day. Administration: Ambrisentan will be administered orally with or without food intake.

  • PlaceboDrug

    Placebo tablet (one to two tablets corresponding to one to two verum tablets). Administration: Placebo will be administrated orally with or without food intake in the morning.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of diagnostic PAH (mPAP ≥25 mmHg)Time frame: baseline, 1 year
  2. Change of Pulmonary vascular resistanceTime frame: baseline, 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nanjing First Hospital

    Nanjing, Jiangsu, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.